Navigation Links
CYPHER(R) Sirolimus Drug-Eluting Stent Remains Unsurpassed in Terms of Clinical Safety and Efficacy
Date:9/30/2010

"CYPHER remains an essential treatment option for today's interventional cardiologist considering its unsurpassed clinical safety and efficacy proven out to 10 years and the 7 extended indications (e.g. diabetes, AMI, multi vessel disease) in which CYPHER(R) stent specifically demonstrated superior outcomes," said Rogers.

Notes to Editors:

CYPHER(R) Sirolimus-eluting Coronary Stent in detail

The CYPHER(R) stent releases a unique anti-inflammatory and anti-proliferative-type medicine, sirolimus, into the artery wall over a period of 90 days. The sirolimus drug helps limit the overgrowth of normal cells while the artery heals. The CYPHER(R) Stent has a unique closed-cell design that allows the medicine to be distributed more evenly across the treated area and that helps to keep the arteries open and the blood flowing to the heart, reducing the chance of re-intervention in the treated area. Eighty percent (80%) of the sirolimus drug is released during the first 30 days. The rest is released by the end of 90 days.

About CYPHER(R) stent studies

The CYPHER(R) Stent is the most studied drug-eluting stent in the world, it has a proven safety profile out to 10 years and has been used in nearly 4 million patients worldwide. Today, with more than 9.000 citations on PubMed, CYPHER(R) Sirolimus-eluting Coronary Stent is recognized as having the most in depth clinical data, which marked it out as the most effective drug-eluting stent available today with a clinical safety profile presenting minimal risks. CYPHER's(R) body of clinical evidence is completely unmatched by any other drug-eluting stent. The CYPHER(R) Stent has consistently proven to control late loss across all vessel sizes and across a broad patient population, even in the most complex types of patients such as patients with diabetes and acute myocardial infarction. In fact, the CYPHER(R) Stent has shown more than 70% risk reduction in target lesion revascularization (TLR) whe
'/>"/>

SOURCE Cordis Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CORDIS Announces Results of Ten-Year CYPHER(R) Sirolimus-Eluting Coronary Stent Follow-Up
2. Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent
3. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
4. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
5. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
6. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
7. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
8. Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeichs Combo™ Bio-engineered Sirolimus Eluting Stent
9. Pre-clinical Data Show OrbusNeichs Combo Bio-engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies
10. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
11. MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014  BC Technical, the largest nationwide, ... America , Inc., a leading provider of Siemens Nuclear ... long-term agreement naming BC Technical as the authorized provider ... MiE and BC Technical announced today that the ... BC Technical as the service and systems provider for ...
(Date:7/10/2014)... 2014 CVS Caremark Corporation (NYSE: CVS ... a quarterly dividend of $0.275 (27.5 cents) per share on ... 1, 2014, to holders of record on July 21, 2014. ... is dedicated to helping people on their path to better ... the United States . Through the company,s more than ...
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( ... "Dental Consumables Market - Global Industry Analysis, Size, Share, ... to their offering. (Logo: ... which are used on patients in order to treat ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
... AMSTERDAM, May 31, 2011 Leading events organiser ... UBM), announced details of a new Logistics and Supply ... event dedicated to pharmaceutical contract services and outsourcing. ICSE ... Messe Frankfurt, Germany and is part of the world,s ...
... 2011 Volcano Corporation (NASDAQ: VOLC ), a ... guidance tools designed to enhance the treatment of coronary and ... in the Goldman Sachs 32nd Annual Global Healthcare Conference on ... 2:40 p.m., Pacific Daylight Time (5:40 p.m., Eastern Daylight Time). ...
Cached Medicine Technology:Logistics and Supply Chain Zone Introduced at ICSE 2011 Event 2Logistics and Supply Chain Zone Introduced at ICSE 2011 Event 3
(Date:7/14/2014)... 14, 2014 According to the Boost Your Bust ... for women who want to learn how to increase the size ... consists of 7 chapters including:, , Chapter 1 ... Chapter 2 – How Natural Breast Enlargement Works , ... Look Bigger , Chapter 4 – The Groundwork , ...
(Date:7/14/2014)... 2014 Reha Technology today announced ... portable and full-featured upper extremity robotic trainer that ... interactive games and challenges in a lightweight and ... , Armotion combines a variety of ... maximize the therapy effect for patients with severe ...
(Date:7/14/2014)... 2014 TherapySites, the ... health professionals, announced today its affiliation with the ... (LPCANC). This new relationship allows TherapySites to ... LPCANC members, adding exclusive benefits and promotional offers. ... been dedicated to providing online marketing solutions specifically ...
(Date:7/14/2014)... Summer is the best season of the year for many. ... other outdoor adventures. The promotional product experts at 4AllPromos ... summer long. The promo product gurus at 4AllPromos have put ... products everyone must have on hand this summer. , ... helps protect skin from harmful UV rays produced by ...
(Date:7/14/2014)... July 14, 2014 Cadeon Associates ... Turning Information into Money,” today announced that it ... global program that helps partners resell, deploy, and ... Spotfire® analytics platform. TIBCO Software Inc. is a ... including TIBCO Spotfire analytics, providing businesses the ability ...
Breaking Medicine News(10 mins):Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 2Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 3Health News:Reha Technology Launches the Armotion™, a Device for the Rehabilitation of the Upper Extremity 2Health News:TherapySites Partners With the Licensed Professional Counselors Association of North Carolina to Make Online Marketing Available to All Therapists 2Health News:Why These Three Summer Essentials from 4AllPromos Can Improve Summer 2Health News:Cadeon Associates Inc. Joins TIBCO Spotfire Partner Network 2Health News:Cadeon Associates Inc. Joins TIBCO Spotfire Partner Network 3
... Dialysis Corporation of,America (Nasdaq: DCAI ) ... located at the St. Thomas More Nursing and,Rehabilitation Center, ... St.,Thomas More Center, as well as the surrounding community. ... 24 treatment stations and is currently caring for,approximately 145 ...
... Inc., a Boston-based,award-winning medical tourism facilitator, has ... an Indianapolis-based health benefits company to provide,global ... affiliated health plan,in Wisconsin. Healthbase will handle ... WellPoint members. , ...
... and flu,season, which means misery for kids and the parents trying ... asking parents to resist the urge to give children under,the age ... Such drugs can have serious side effects on the smallest ... drowsiness,difficulty breathing and even death. , "Some ...
... 5 Health-conscious consumers who are,tired of taking several ... smaller,more powerful alternative to fish oil supplements in MegaRed(TM) ... fatty acids combined with,powerful antioxidants, and is three times ... softgel per day -- which is about as small ...
... Jan. 5 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) ... updates where amongst other things the company addressed several ... that it has finalized its bilateral negotiations with Slavica ... Chem is a spin off of Renuyu Biochem, a ...
... Soliris(R) INCLINE VILLAGE, Nev., and CHESHIRE, Conn., Jan. 5 ... Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ) today ... license agreement and settlement agreement that resolve the legal disputes ... PDL,s patents known as the Queen et al. patents. ...
Cached Medicine News:Health News:Dialysis Corporation of America Announces Acquisition of Maryland Dialysis Center 2Health News:Healthbase Collaborates with WellPoint to Bring Affordable Medical Tourism Solutions 2Health News:Caution Urged When Giving Kids Cold and Flu Meds 2Health News:Three Times More Powerful Than Fish Oil, MegaRed(TM) Omega-3 Krill Oil Now Available Nationwide 2Health News:Three Times More Powerful Than Fish Oil, MegaRed(TM) Omega-3 Krill Oil Now Available Nationwide 3Health News:Hard To Treat Diseases (HTDS) Completes E Europe Merger 2Health News:Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute 2Health News:Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute 3
... The table-mounted knee ... exposure for total knee ... flexible, open-frame design allows ... the knee during the ...
... NGAL (neutrophil gelatinase-associated lipocalin, lipocalin-2) is a ... predicting acute renal failure with a >90% ... especially in urine, as early as 2 ... an ideal diagnostic marker for acute renal ...
... an assayed quality control material used for ... hemoglobin fractions on CO-Oximeter instrumentation. It provides ... that parallels the human physiologic range for ... available in three (3) levels for monitoring ...
... is an assayed quality control ... measurements of total hemoglobin and ... It is available in three ... performance at varying points within ...
Medicine Products: